| Medication |
Trade name |
Primary Indication |
Company |
2015 |
2014 |
2013 |
2012 |
2011 |
2010 |
2009 |
2008[1][2][3][4][5][6] |
2007[7][8][9][10][11][12] |
2006[13][14][15][16][17][18] |
2005[19][20][21][22][23] |
2004[24][25][26][27] |
2003[28][29][30][31] |
2002[32][33][34][35] |
2001[36] |
2000[37][38] |
| atorvastatin |
Lipitor |
Reduction of LDL cholesterol |
Pfizer |
|
|
|
|
|
|
|
$12,401 |
$12,675 |
$12,886 |
$12,187 |
$10,862 |
$9,231 |
$7,972 |
$6,448 |
$5,028 |
| sunitinib malate |
Sutent |
Advanced and/or metastatic renal cell carcinoma (mRCC) & refractory gastrointestinal stromal tumors (GIST) |
Pfizer |
|
|
|
|
|
|
|
$847 |
$581 |
$219 |
|
|
|
|
|
|
| irinotecan |
Camptosar |
Metastatic colorectal cancer |
Pfizer |
|
|
|
|
|
|
|
$563 |
$969 |
$903 |
$910 |
$554 |
$299 |
|
|
|
| bimatoprost |
Lumigan |
Open-angle glaucoma or ocular hypertension |
Allergan |
|
|
|
|
|
|
|
$426.2 |
$391.7 |
$327.5 |
$267.6 |
$232.9 |
$181.3 |
$123 |
$35.4 |
|
| exemestane |
Aromasin |
Breast cancer |
Pfizer |
|
|
|
|
|
|
|
$465 |
$401 |
$320 |
$247 |
$143 |
$58 |
|
|
|
| epirubicin |
Ellence |
Breast cancer |
Pfizer |
|
|
|
|
|
|
|
|
|
$312 |
$367 |
$344 |
$216 |
|
|
|
| trastuzumab |
Herceptin |
HER2-positive metastatic breast cancer |
Genentech |
|
|
|
|
|
|
|
$1,382 |
$1,287 |
$1,234 |
$747.2 |
$483.2 |
$424.8 |
$385.2 |
$346.7 |
$276 |
| gemcitabine |
Gemzar |
Ovarian cancer, non-small cell lung cancer (NSCLC), metastatic breast cancer (MBC), and pancreatic cancer |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$1,719.8 |
$1,592.4 |
$1,408.1 |
$1,334.5 |
$1,214.4 |
$1,021.7 |
$875 |
$723 |
$559.3 |
| bevacizumab |
Avastin |
Metastatic colorectal cancer, non-small cell lung cancer (NSCLC), renal cell carcinoma, HER2-negative breast cancer |
Genentech |
|
|
|
|
|
|
|
$2,686 |
$2,296 |
$1,746 |
$1,132 |
$554.6 |
|
|
|
|
| erlotinib |
Tarceva |
Advanced (metastatic) non-small cell lung cancer (NSCLC) |
Genentech |
|
|
|
|
|
|
|
$457 |
$417 |
$402 |
$274.9 |
$13.3 |
|
|
|
|
| brimonidine |
Alphagan |
Open-angle glaucoma or ocular hypertension |
Allergan |
|
|
|
|
|
|
|
|
|
|
|
|
$286.8 |
$248.5 |
$250.9 |
|
| rituximab |
Rituxan |
Non-Hodgkin's lymphoma and rheumatoid arthritis |
Genentech |
|
|
|
|
|
|
|
$2,587 |
$2,285 |
$2,071 |
$1,831.4 |
$1,574 |
$1,360.2 |
$1,162.9 |
$818.6 |
|
| ranibizumab |
Lucentis |
Age-related macular degeneration (AMD) |
Genentech |
|
|
|
|
|
|
|
$875 |
$815 |
$380 |
|
|
|
|
|
|
| omalizumab |
Xolair |
Asthma |
Genentech |
|
|
|
|
|
|
|
$517 |
$472 |
$425 |
$320.6 |
$187.6 |
$25.1 |
|
|
|
| somatropin |
Nutropin |
Growth hormone deficiency, chronic kidney disease |
Genentech |
|
|
|
|
|
|
|
$358 |
$371 |
$378 |
$370.5 |
$348.8 |
$319.5 |
|
|
|
| dornase alfa |
Pulmozyme |
Cystic fibrosis (CF) |
Genentech |
|
|
|
|
|
|
|
$257 |
$223 |
$199 |
$186.5 |
$157.1 |
$143.7 |
$138.1 |
$123 |
|
| efalizumab |
Raptiva |
Plaque psoriasis |
Genentech |
|
|
|
|
|
|
|
$108 |
$107 |
$90 |
$79.2 |
$52.4 |
$1.4 |
|
|
|
| montelukast |
Singulair |
Asthma |
Merck |
|
|
|
|
|
|
|
$4,336.9 |
$4,266.3 |
$3,579 |
$2,975.6 |
$2,622 |
|
|
|
|
| alendronate sodium |
Fosamax |
Postmenopausal osteoporosis |
Merck |
|
|
|
|
|
|
|
$1,552.7 |
$3,049 |
$3,134.4 |
$3,191.2 |
$3,159.7 |
|
|
|
|
| sitagliptin |
Januvia |
Type 2 diabetes |
Merck |
|
|
|
|
|
|
|
$1,397.1 |
$667.5 |
$42.9 |
|
|
|
|
|
|
| simvastatin |
Zocor |
Reduction of LDL cholesterol |
Merck |
|
|
|
|
|
|
|
$660.1 |
$876.5 |
$2,802.7 |
$4,381.7 |
$5,196.5 |
|
|
|
|
| rizatriptan benzoate |
Maxalt |
Migraine pain |
Merck |
|
|
|
|
|
|
|
$529.2 |
$467.3 |
$406.4 |
$348.4 |
$309.9 |
|
|
|
|
| finasteride |
Propecia |
Hair loss |
Merck |
|
|
|
|
|
|
|
$429.1 |
$405.4 |
$351.8 |
$291.9 |
$270.2 |
|
|
|
|
| etoricoxib |
Arcoxia |
Osteoarthritis and rheumatoid arthritis |
Merck |
|
|
|
|
|
|
|
$377.3 |
$329.1 |
$265.4 |
$218.2 |
|
|
|
|
|
| sitagliptin/metformin HCl |
Janumet |
Type 2 diabetes |
Merck |
|
|
|
|
|
|
|
$351.1 |
$86.4 |
|
|
|
|
|
|
|
| finasteride |
Proscar |
Benign prostatic hyperplasia (enlarged prostate) |
Merck |
|
|
|
|
|
|
|
$323.5 |
$411 |
$618.5 |
$741.4 |
$733.1 |
|
|
|
|
| aprepitant |
Emend |
Nausea and vomiting prevention caused by chemotherapy |
Merck |
|
|
|
|
|
|
|
$263.8 |
$204.2 |
$130.8 |
$87 |
|
|
|
|
|
| olanzapine |
Zyprexa |
Schizophrenia |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$4,696.1 |
$4,761 |
$4,363.6 |
$4,202.3 |
$4,419.8 |
$4,276.9 |
$3,689 |
$3,087 |
$2,349.5 |
| duloxetine HCl |
Cymbalta |
Depression and generalized anxiety disorder |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$2,697.1 |
$2,102.9 |
$1,316.4 |
$679.7 |
$93.9 |
|
|
|
|
| insulin lispro |
Humalog |
Type 1 diabetes in adults |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$1,735.8 |
$1,474.6 |
$1,299.5 |
$1,197.7 |
$1,101.6 |
$1,021.3 |
$834 |
$628 |
$350.2 |
| pemetrexed |
Alimta |
Locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$1,154.7 |
$854 |
$611.8 |
$463.2 |
$142.6 |
|
|
|
|
| raloxifene HCl |
Evista |
Osteoporosis |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$1,075.6 |
$1,090.7 |
$1,045.3 |
$1,036.1 |
$1,012.7 |
$922.1 |
$822 |
$665 |
$521.5 |
| insulin isophane |
Humulin |
Diabetes |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$1,063.2 |
$985.2 |
$925.3 |
$1,004.7 |
$997.7 |
$1,060.4 |
$1,004 |
$1,061 |
$1,114.5 |
| teriparatide |
Forteo |
Osteoporosis |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$778.7 |
$709.3 |
$594.3 |
$389.3 |
$238.6 |
$65.3 |
|
|
|
| atomoxetine HCl |
Strattera |
Attention-deficit/hyperactivity disorder (ADHD) |
Eli Lilly & Co. |
|
|
|
|
|
|
|
$579.5 |
$569.4 |
$579 |
$552.1 |
$666.7 |
$370.3 |
|
|
|
| timolol |
Istalol |
Open-angle glaucoma |
Ista Pharmaceutical |
|
|
|
|
|
|
|
$14.6 |
$11.3 |
$8.3 |
$2.6 |
|
|
|
|
|
| bromfenac |
Xibrom |
Ocular inflammation |
Ista Pharmaceutical |
|
|
|
|
|
|
|
$63 |
$42.1 |
$20.2 |
$5.3 |
|
|
|
|
|
| hyaluronidase |
Vitrase |
Spreading agent |
Ista Pharmaceutica |
|
|
|
|
|
|
|
$5.2 |
$5.2 |
$4.2 |
$2.5 |
|
|
|
|
|
| rivaroxaban |
Xarelto |
Deep vein thrombosis |
Johnson & Johnson[39] |
$1,868 |
$1,522 |
$864 |
$239 |
$25 |
|
|
|
|
|
|
|
|
|
|
|